J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 30.32 CNY 0.83% Market Closed
Market Cap: 24.2B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note
Jafron Biomedical Co Ltd
/
Income Statement
/
Income from Continuing Operations

Jafron Biomedical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jafron Biomedical Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Income from Continuing Operations
¥794.1m
CAGR 3-Years
-11%
CAGR 5-Years
9%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Income from Continuing Operations
¥522.1m
CAGR 3-Years
71%
CAGR 5-Years
99%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Income from Continuing Operations
¥1.7B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
19%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Income from Continuing Operations
¥12.4B
CAGR 3-Years
16%
CAGR 5-Years
23%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Income from Continuing Operations
¥672.5m
CAGR 3-Years
-29%
CAGR 5-Years
-17%
CAGR 10-Years
5%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Income from Continuing Operations
¥2B
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.5B CNY
Industry
Health Care

In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.

Intrinsic Value
48.46 CNY
Undervaluation 37%
Intrinsic Value
Price
J
What is Intrinsic Value?

See Also

What is Jafron Biomedical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
794.1m CNY

Based on the financial report for Sep 30, 2024, Jafron Biomedical Co Ltd's Income from Continuing Operations amounts to 794.1m CNY.

What is Jafron Biomedical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
9%

Over the last year, the Income from Continuing Operations growth was 84%. The average annual Income from Continuing Operations growth rates for Jafron Biomedical Co Ltd have been -11% over the past three years , 9% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.